Evidence map›Paper›PMID 29556048›Full record

ArticleProstate cancer and prostatic diseases2018

Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.

Benjamin Benzon, Stephanie A Glavaris, Brian W Simons, Robert M Hughes, Kamyar Ghabili, Patrick Mullane, Rebecca Miller, Katriana Nugent, Brian Shinder, Jeffrey Tosoian and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Benjamin BenzonBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. benzon.benjamin@gmail.com.
Stephanie A GlavarisBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brian W SimonsBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-0644-211X
Robert M HughesBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kamyar GhabiliBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4544-8389
Patrick MullaneBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rebecca MillerBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Katriana NugentDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Hospital School of Medicine, Baltimore, MD, USA.
Brian ShinderBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jeffrey TosoianBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ephraim J FuchsSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital School of Medicine, Baltimore, MD, USA.
Phuoc T TranBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0147-0376
Paula J HurleyBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Milena Vuica-RossDepartment of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5308-8550
Edward M SchaefferDepartment of Urology, Northwestern Feinberg School of Medicine, Chicago, IL, USA.
Charles G DrakeBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ashley E RossBrady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USJohns Hopkins Hospital · USNorthwestern University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
Structure-Functions Studies of Twist1-induced Radioresistance in Lung CancerR01CA166348 · NCI · JOHNS HOPKINS UNIVERSITY · PI TRAN, PHUOC T. · 2013 to 2017
$1.7M
NCI NIH HHS P50 CA180995NCI NIH HHS R01 CA166348NIGMS NIH HHS T32 GM007309NIGMS NIH HHS T32 GM008752
6 · The paper itself

Abstract

backgroundProstate cancer remains the second leading cause of cancer related death in men. Immune check point blocking antibodies have revolutionized treatment of multiple solid tumors, but results in prostate cancer remain marginal. Previous reports have suggested that local therapies, in particular cryoablation might increase tumor immunogenicity. In this work, we examine potential synergism between tumor cryoabalation and check point blocking antibodies.

methodsFVB/NJ mice were injected subcutaneously into each flank with either 1 × 10

resultsTreatment with anti-CTLA-4 antibody and cryoablation delayed the growth of the distant tumor by 14.8 days (p = 0.0006) and decreased the mortality rate by factor of 4 (p = 0.0003) when compared to cryoablation alone. This synergy was found to be dependent on CD3

conclusionTrimodal therapy consisting of androgen deprivation, cryoablation and PD-1 blockade, as well as the combination of cryoablation and low dose anti-CTLA-4 blockade showed that local therapies with cryoablation could be considered to augment the effects of checkpoint blockade in prostate cancer.

Indexed as

AnimalsCD8-Positive T-LymphocytesCell Line, TumorCombined Modality TherapyCryosurgeryCTLA-4 AntigenDisease Models, AnimalHumansImmunotherapyKaplan-Meier EstimateMaleMiceNeoplasms, Hormone-DependentProstatic NeoplasmsCTLA-4 AntigenCtla4 protein, mouse

Identifiers

PMID29556048
PMCPMC5990963
OpenAlexW2791298847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.